ES2317564T3 - 3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones. - Google Patents

3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones. Download PDF

Info

Publication number
ES2317564T3
ES2317564T3 ES06765213T ES06765213T ES2317564T3 ES 2317564 T3 ES2317564 T3 ES 2317564T3 ES 06765213 T ES06765213 T ES 06765213T ES 06765213 T ES06765213 T ES 06765213T ES 2317564 T3 ES2317564 T3 ES 2317564T3
Authority
ES
Spain
Prior art keywords
dihydrotetrabenazine
cis
inflammatory
isomer
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06765213T
Other languages
English (en)
Spanish (es)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Laboratories Ireland Ltd
Original Assignee
Cambridge Laboratories Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories Ireland Ltd filed Critical Cambridge Laboratories Ireland Ltd
Application granted granted Critical
Publication of ES2317564T3 publication Critical patent/ES2317564T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES06765213T 2005-08-05 2006-08-04 3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones. Expired - Lifetime ES2317564T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516168.2A GB0516168D0 (en) 2005-08-05 2005-08-05 Pharmaceutical compounds
GB0516168 2005-08-05

Publications (1)

Publication Number Publication Date
ES2317564T3 true ES2317564T3 (es) 2009-04-16

Family

ID=34984180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06765213T Expired - Lifetime ES2317564T3 (es) 2005-08-05 2006-08-04 3,11b.cis.dihidrotetrabenazina para el tratamiento de enfermedades proliferativas o inflamaciones.

Country Status (23)

Country Link
US (1) US20090275605A1 (enExample)
EP (2) EP1964565A1 (enExample)
JP (1) JP2009503045A (enExample)
KR (1) KR20080033501A (enExample)
CN (1) CN101321528B (enExample)
AT (1) ATE412414T1 (enExample)
AU (1) AU2006277836B8 (enExample)
CA (1) CA2620952A1 (enExample)
CY (1) CY1108729T1 (enExample)
DE (1) DE602006003415D1 (enExample)
DK (1) DK1861100T3 (enExample)
ES (1) ES2317564T3 (enExample)
GB (1) GB0516168D0 (enExample)
HR (1) HRP20090017T3 (enExample)
MX (1) MX2008001546A (enExample)
NZ (1) NZ566010A (enExample)
PL (1) PL1861100T3 (enExample)
PT (1) PT1861100E (enExample)
RS (1) RS50720B (enExample)
RU (1) RU2409364C2 (enExample)
SI (1) SI1861100T1 (enExample)
WO (1) WO2007017643A1 (enExample)
ZA (2) ZA200801170B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US10550120B2 (en) 2016-03-25 2020-02-04 Tohoku University Indole alkaloid compound having immune checkpoint inhibitory action
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009918A (en) * 1961-11-21 Chz ch
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3132147A (en) * 1964-05-05
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3123609A (en) * 1964-03-03 Benzo
US3159638A (en) * 1964-12-01 Xcha-chj
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2843591A (en) 1958-07-15 Method for preparing same
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma

Also Published As

Publication number Publication date
CY1108729T1 (el) 2014-04-09
DE602006003415D1 (de) 2008-12-11
DK1861100T3 (da) 2008-12-15
AU2006277836A1 (en) 2007-02-15
ZA200801171B (en) 2009-08-26
HK1111084A1 (en) 2008-08-01
CN101321528B (zh) 2011-05-25
NZ566010A (en) 2010-05-28
GB0516168D0 (en) 2005-09-14
PL1861100T3 (pl) 2009-06-30
SI1861100T1 (sl) 2009-04-30
HRP20090017T3 (hr) 2009-03-31
EP1861100B1 (en) 2008-10-29
RS50720B (sr) 2010-08-31
ZA200801170B (en) 2009-12-30
RU2008108516A (ru) 2009-09-10
MX2008001546A (es) 2008-04-04
AU2006277836B2 (en) 2011-11-10
ATE412414T1 (de) 2008-11-15
WO2007017643A1 (en) 2007-02-15
CA2620952A1 (en) 2007-02-15
RU2409364C2 (ru) 2011-01-20
CN101321528A (zh) 2008-12-10
PT1861100E (pt) 2008-12-26
EP1964565A1 (en) 2008-09-03
KR20080033501A (ko) 2008-04-16
AU2006277836B8 (en) 2011-12-08
EP1861100A1 (en) 2007-12-05
JP2009503045A (ja) 2009-01-29
US20090275605A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
ES2313292T3 (es) Dihidrotetrabenazinas y composiciones farmaceuticas que las contienen .
ES2314931T3 (es) Utilizacion de 3,11b-cis-dihidrotetrabenazina para el tratamiento de sintomas de la enfermedad de huntington.
WO2021228161A1 (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
UA121138C2 (uk) Нафтиридинові сполуки як інгібітори jak-кінази
ES2318771T3 (es) 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
CN114206850B (zh) 作为crac抑制剂的2h-苯并吡喃衍生物
EP1861100B1 (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
CN116940568A (zh) 呋喃稠环取代的戊二酰亚胺类化合物
CN110372557B (zh) 环己烷胺类d3/d2受体部分激动剂
CN104341434B (zh) 取代的雷帕霉素三氮唑衍生物和用途
WO2025149082A1 (zh) 取代桥环类抑制剂及其制备方法和应用
WO2008092335A1 (en) Novel vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives
CN109096219B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
TW202413366A (zh) 含氮雜環化合物作為泛素－特異性蛋白酶１抑制劑的製備方法、應用及其用途
CN106243108A (zh) 一种高纯度的替格瑞洛及其制备方法
WO2007104214A1 (en) Camptothecin derivatives and their use
KR102805214B1 (ko) Mll1 억제제 및 항암제
CN118304315A (zh) 一种核苷类化合物在制备抗呼吸道合胞病毒感染相关产品上的用途
CN103764608B (zh) 用于治疗炎性肠病的茚衍生物
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
WO2008143916A2 (en) Prokinetic agent for bowel preparation
CN116120327B (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
CN115087640B (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN111057069B (zh) 一种环状化合物、其应用及组合物
CN107163047A (zh) 槐定胺类衍生物及其制备方法和用途